Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entia Biosciences's change in inventory for the quarter that ended in Dec. 2016 was $-0.01 Mil. It means Entia Biosciences's inventory
increased by $0.01 Mil
from Sep. 2016 to Dec. 2016 .
Entia Biosciences's change in inventory for the fiscal year that ended in Dec. 2016 was $0.03 Mil. It means Entia Biosciences's inventory
declined by $0.03 Mil
from Dec. 2015 to Dec. 2016 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Entia Biosciences's Days Inventory for the quarter that ended in Dec. 2016 was 451.69.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Entia Biosciences's Inventory Turnover for the quarter that ended in Dec. 2016 was 0.20.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Entia Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2016 was 1.08.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Entia Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entia Biosciences Change In Inventory Related Terms
Entia Biosciences Change In Inventory Historical Data
* Premium members only.
The historical data trend for Entia Biosciences's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $0.03 Mil mean?
Entia Biosciences (ERGO) has a Change In Inventory of $0.03 Mil as of Dec. 2016. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Entia Biosciences and its competitors.
Is Entia Biosciences' Change In Inventory too high?
Entia Biosciences' current Change In Inventory is $0.03 Mil.
How does Entia Biosciences' Change In Inventory compare to OBMP and NSPX?
Entia Biosciences' Change In Inventory of $0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Entia Biosciences and its competitors. Entia Biosciences's current Change In Inventory is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Change In Inventory of $0.03 Mil. The current Change In Inventory is $0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Change In Inventory is $0.03 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERGO has been successfully added to your 
